{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T17:49:09Z","timestamp":1772214549046,"version":"3.50.1"},"reference-count":65,"publisher":"Public Library of Science (PLoS)","issue":"9","license":[{"start":{"date-parts":[[2022,9,6]],"date-time":"2022-09-06T00:00:00Z","timestamp":1662422400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"ERC H2020"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:p>\n                    Inducing senescence in cancer cells is emerging as a new therapeutic strategy. In order to find ways to enhance senescence induction by palbociclib, a CDK4\/6 inhibitor approved for treatment of metastatic breast cancer, we performed functional genetic screens in palbociclib-resistant cells. Using this approach, we found that loss of\n                    <jats:italic>CDK2<\/jats:italic>\n                    results in strong senescence induction in palbociclib-treated cells. Treatment with the CDK2 inhibitor indisulam, which phenocopies genetic CDK2 inactivation, led to sustained senescence induction when combined with palbociclib in various cell lines and lung cancer xenografts. Treating cells with indisulam led to downregulation of cyclin H, which prevented CDK2 activation. Combined treatment with palbociclib and indisulam induced a senescence program and sensitized cells to senolytic therapy. Our data indicate that inhibition of CDK2 through indisulam treatment can enhance senescence induction by CDK4\/6 inhibition.\n                  <\/jats:p>","DOI":"10.1371\/journal.pone.0273182","type":"journal-article","created":{"date-parts":[[2022,9,6]],"date-time":"2022-09-06T13:41:17Z","timestamp":1662471677000},"page":"e0273182","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":12,"title":["Indisulam synergizes with palbociclib to induce senescence through inhibition of CDK2 kinase activity"],"prefix":"10.1371","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3240-9233","authenticated-orcid":true,"given":"Ziva","family":"Pogacar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jackie L.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6696-0512","authenticated-orcid":true,"given":"Lenno","family":"Krenning","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2647-228X","authenticated-orcid":true,"given":"Giulia","family":"De Conti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fleur","family":"Jochems","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cor","family":"Lieftink","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arno","family":"Velds","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8535-9607","authenticated-orcid":true,"given":"Leyma","family":"Wardak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7177-938X","authenticated-orcid":true,"given":"Kelvin","family":"Groot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arnout","family":"Schepers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9881-6432","authenticated-orcid":true,"given":"Liqin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ji-Ying","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marieke","family":"van de Ven","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1037-6269","authenticated-orcid":true,"given":"Olaf","family":"van Tellingen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rene H.","family":"Medema","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roderick L.","family":"Beijersbergen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rene","family":"Bernards","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9696-2014","authenticated-orcid":true,"given":"Rodrigo","family":"Leite de Oliveira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2022,9,6]]},"reference":[{"key":"pone.0273182.ref001","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1093\/jnci\/djq364","article-title":"Therapy-induced senescence in cancer","volume":"102","author":"JA Ewald","year":"2010","journal-title":"J Natl Cancer Inst"},{"key":"pone.0273182.ref002","doi-asserted-by":"crossref","first-page":"5975","DOI":"10.1038\/onc.2008.213","article-title":"Critical pathways in cellular senescence and immortalization revealed by gene expression profiling","volume":"27","author":"AL Fridman","year":"2008","journal-title":"Oncogene"},{"key":"pone.0273182.ref003","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/nature25167","article-title":"Senescence-associated reprogramming promotes cancer stemness","author":"M Milanovic","year":"2018","journal-title":"Nature"},{"key":"pone.0273182.ref004","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1038\/s41586-019-1607-3","article-title":"Inducing and exploiting vulnerabilities for the treatment of liver cancer","volume":"574","author":"C Wang","year":"2019","journal-title":"Nature"},{"key":"pone.0273182.ref005","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1038\/s42255-019-0122-z","article-title":"Cardiac glycosides are broad-spectrum senolytics","volume":"1","author":"A Guerrero","year":"2019","journal-title":"Nat Metab"},{"key":"pone.0273182.ref006","doi-asserted-by":"crossref","first-page":"822","DOI":"10.3390\/cancers12040822","article-title":"Therapy-Induced Senescence: An \u201cOld\u201d Friend Becomes the Enemy","volume":"12","author":"T Saleh","year":"2020","journal-title":"Cancers"},{"key":"pone.0273182.ref007","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1158\/1541-7786.MCR-16-0319","article-title":"Stromal Senescence By Prolonged CDK4\/6 Inhibition Potentiates Tumor Growth","volume":"15","author":"X Guan","year":"2017","journal-title":"Mol Cancer Res"},{"key":"pone.0273182.ref008","first-page":"10","article-title":"A versatile drug delivery system targeting senescent cells","author":"D Mu\u00f1oz-Esp\u00edn","year":"2018","journal-title":"EMBO Mol Med"},{"key":"pone.0273182.ref009","first-page":"37","article-title":"Thermal proteome profiling of breast cancer cells reveals proteasomal activation by CDK4\/6 inhibitor palbociclib","author":"TP Miettinen","year":"2018","journal-title":"EMBO J"},{"key":"pone.0273182.ref010","doi-asserted-by":"crossref","first-page":"69493","DOI":"10.18632\/oncotarget.17778","article-title":"Preclinical characterization of abemaciclib in hormone receptor positive breast cancer","volume":"8","author":"R Torres-Guzm\u00e1n","year":"2017","journal-title":"Oncotarget"},{"key":"pone.0273182.ref011","doi-asserted-by":"crossref","first-page":"15658","DOI":"10.18632\/oncotarget.24585","article-title":"CDK4\/6 inhibition as maintenance and combination therapy for high grade serous ovarian cancer","volume":"9","author":"M Iyengar","year":"2018","journal-title":"Oncotarget"},{"key":"pone.0273182.ref012","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/35106065","article-title":"To cycle or not to cycle: a critical decision in cancer","volume":"1","author":"M Malumbres","year":"2001","journal-title":"Nat Rev Cancer"},{"key":"pone.0273182.ref013","first-page":"2875","article-title":"MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+\/HER2\u2212 Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy","volume":"35","author":"GW Sledge","year":"2017","journal-title":"J Clin Orthod"},{"key":"pone.0273182.ref014","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1093\/annonc\/mdy012","article-title":"Impact of palbociclib plus letrozole on patient-reported health-related quality of life: results from the PALOMA-2 trial","volume":"29","author":"HS Rugo","year":"2018","journal-title":"Ann Oncol"},{"key":"pone.0273182.ref015","first-page":"1022","article-title":"First-line ribociclib (RIB) + letrozole (LET) in hormone receptor-positive (HR+), HER2-negative (HER2\u2013) advanced breast cancer (ABC): MONALEESA-2 biomarker analyses","volume":"36","author":"GN Hortobagyi","year":"2018","journal-title":"J Clin Orthod"},{"key":"pone.0273182.ref016","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1158\/2159-8290.CD-15-0894","article-title":"Targeting CDK4 and CDK6: From Discovery to Therapy","volume":"6","author":"CJ Sherr","year":"2016","journal-title":"Cancer Discov"},{"key":"pone.0273182.ref017","doi-asserted-by":"crossref","first-page":"608","DOI":"10.3389\/fonc.2018.00608","article-title":"CDK 4\/6 Inhibitors as Single Agent in Advanced Solid Tumors","volume":"8","author":"F Schettini","year":"2018","journal-title":"Front Oncol"},{"key":"pone.0273182.ref018","doi-asserted-by":"crossref","first-page":"8077","DOI":"10.1200\/jco.2014.32.15_suppl.8077","article-title":"A phase II clinical trial of the CDK 4\/6 inhibitor palbociclib (PD 0332991) in previously treated, advanced non-small cell lung cancer (NSCLC) patients with inactivated CDKN2A","author":"PK Gopalan","year":"2014","journal-title":"Journal of Clinical Oncology"},{"key":"pone.0273182.ref019","first-page":"5557","article-title":"A multicenter open-label phase II study of the efficacy and safety of palbociclib a cyclin-dependent kinases 4 and 6 inhibitor in patients with recurrent ovarian cancer","volume":"34","author":"GE Konecny","year":"2016","journal-title":"J Clin Orthod"},{"key":"pone.0273182.ref020","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1200\/JCO.18.00925","article-title":"Cyclin E1 Expression and Palbociclib Efficacy in Previously Treated Hormone Receptor-Positive Metastatic Breast Cancer","volume":"37","author":"NC Turner","year":"2019","journal-title":"J Clin Oncol"},{"key":"pone.0273182.ref021","doi-asserted-by":"crossref","first-page":"7810","DOI":"10.1007\/s12035-019-1633-z","article-title":"Palbociclib Effectively Halts Proliferation but Fails to Induce Senescence in Patient-Derived Glioma Stem Cells","volume":"56","author":"O Morris-Hanon","year":"2019","journal-title":"Mol Neurobiol"},{"key":"pone.0273182.ref022","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abb2210","article-title":"Increased lysosomal biomass is responsible for the resistance of triple-negative breast cancers to CDK4\/6 inhibition","volume":"6","author":"A Fassl","year":"2020","journal-title":"Sci Adv"},{"key":"pone.0273182.ref023","doi-asserted-by":"crossref","first-page":"31572","DOI":"10.18632\/oncotarget.25803","article-title":"Palbociclib resistance confers dependence on an FGFR-MAP kinase-mTOR-driven pathway in KRAS-mutant non-small cell lung cancer","volume":"9","author":"E Haines","year":"2018","journal-title":"Oncotarget"},{"key":"pone.0273182.ref024","article-title":"Early adaptation and acquired resistance to CDK4\/6 inhibition in estrogen receptor\u2013positive breast cancer","author":"MT Herrera-Abreu","year":"2016","journal-title":"Cancer Res"},{"key":"pone.0273182.ref025","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.ccr.2014.05.020","article-title":"CDK 4\/6 inhibitors sensitize PIK3CA mutant breast cancer to PI3K inhibitors","volume":"26","author":"SR Vora","year":"2014","journal-title":"Cancer Cell"},{"key":"pone.0273182.ref026","unstructured":"Ruscetti M, Leibold J, Bott MJ, Fennell M. NK cell\u2013mediated cytotoxicity contributes to tumor control by a cytostatic drug combination. 2018. Available: https:\/\/science.sciencemag.org\/content\/362\/6421\/1416.abstract?casa_token=xqbhMa9rLysAAAAA:IicKqq8A-eetp0IF500MdGNsn5Sru5wY1fplLa9ZFxJM_5iDyOXKOSmmRNv9zk6_mnnG_xLDzdZNNqU"},{"key":"pone.0273182.ref027","doi-asserted-by":"crossref","first-page":"39595","DOI":"10.18632\/oncotarget.9153","article-title":"Efficacy of the combination of MEK and CDK4\/6 inhibitors in vitro and in vivo in KRAS mutant colorectal cancer models","volume":"7","author":"MS Lee","year":"2016","journal-title":"Oncotarget"},{"key":"pone.0273182.ref028","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1023\/A:1010608317361","article-title":"Mechanisms of action of the novel sulfonamide anticancer agent E7070 on cell cycle progression in human non-small cell lung cancer cells","volume":"19","author":"K Fukuoka","year":"2001","journal-title":"Invest New Drugs"},{"key":"pone.0273182.ref029","doi-asserted-by":"crossref","first-page":"4680","DOI":"10.1158\/1078-0432.CCR-04-0229","article-title":"A phase II clinical and pharmacodynamic study of E7070 in patients with metastatic, recurrent, or refractory squamous cell carcinoma of the head and neck: modulation of retinoblastoma protein phosphorylation by a novel chloroindolyl sulfonamide cell cycle inhibitor","volume":"10","author":"RI Haddad","year":"2004","journal-title":"Clin Cancer Res"},{"key":"pone.0273182.ref030","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1093\/annonc\/mdi016","article-title":"Phase II study of E7070 in patients with metastatic melanoma","volume":"16","author":"JF Smyth","year":"2005","journal-title":"Ann Oncol"},{"key":"pone.0273182.ref031","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1158\/1078-0432.CCR-06-0249","article-title":"A Randomized Phase II Pharmacokinetic and Pharmacodynamic Study of Indisulam as Second-Line Therapy in Patients with Advanced Non\u2013Small Cell Lung Cancer","volume":"13","author":"DC Talbot","year":"2007","journal-title":"Clin Cancer Res"},{"key":"pone.0273182.ref032","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1023\/A:1012287111922","article-title":"Phase I and pharmacokinetic study of E7070, a novel sulfonamide, given at a daily times five schedule in patients with solid tumors. A study by the EORTC-Early Clinical Studies Group (ECSG)","author":"CJA Punt","year":"2001","journal-title":"Annals of Oncology"},{"key":"pone.0273182.ref033","doi-asserted-by":"crossref","first-page":"3508","DOI":"10.1200\/JCO.2002.09.030","article-title":"Phase I and pharmacokinetic study of E7070, a novel chloroindolyl sulfonamide cell-cycle inhibitor, administered as a one-hour infusion every three weeks in patients with advanced cancer","volume":"20","author":"E Raymond","year":"2002","journal-title":"J Clin Oncol"},{"key":"pone.0273182.ref034","first-page":"5195","article-title":"Phase I and pharmacokinetic study of E7070, a chloroindolyl-sulfonamide anticancer agent, administered on a weekly schedule to patients with solid tumors","volume":"9","author":"C Dittrich","year":"2003","journal-title":"Clin Cancer Res"},{"key":"pone.0273182.ref035","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1111\/j.1349-7006.2005.00109.x","article-title":"Phase I pharmacokinetic and pharmacogenomic study of E7070 administered once every 21 days","volume":"96","author":"Y Yamada","year":"2005","journal-title":"Cancer Sci"},{"key":"pone.0273182.ref036","first-page":"356","article-title":"Anticancer sulfonamides target splicing by inducing RBM39 degradation via recruitment to DCAF15","author":"T Han","year":"2017","journal-title":"Science"},{"key":"pone.0273182.ref037","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/nature10868","article-title":"Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR","volume":"483","author":"A Prahallad","year":"2012","journal-title":"Nature"},{"key":"pone.0273182.ref038","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/j.cell.2019.10.005","article-title":"Cellular Senescence: Defining a Path Forward","volume":"179","author":"V Gorgoulis","year":"2019","journal-title":"Cell"},{"key":"pone.0273182.ref039","doi-asserted-by":"crossref","first-page":"11476","DOI":"10.1093\/nar\/gkz879","article-title":"Transcriptome signature of cellular senescence","volume":"47","author":"G Casella","year":"2019","journal-title":"Nucleic Acids Res"},{"key":"pone.0273182.ref040","doi-asserted-by":"crossref","first-page":"3927","DOI":"10.4161\/15384101.2014.973327","article-title":"Gene expression profiling of replicative and induced senescence","volume":"13","author":"M Purcell","year":"2014","journal-title":"Cell Cycle"},{"key":"pone.0273182.ref041","doi-asserted-by":"crossref","DOI":"10.1016\/j.cub.2017.07.033","article-title":"Unmasking Transcriptional Heterogeneity in Senescent Cells","volume":"27","author":"A Hernandez-Segura","year":"2017","journal-title":"Curr Biol"},{"key":"pone.0273182.ref042","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.drudis.2019.12.001","article-title":"Targeting CDK2 in cancer: challenges and opportunities for therapy","volume":"25","author":"S Tadesse","year":"2020","journal-title":"Drug Discov Today"},{"key":"pone.0273182.ref043","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1158\/0008-5472.CAN-20-2275","article-title":"Functional Determinants of Cell Cycle Plasticity and Sensitivity to CDK4\/6 Inhibition","volume":"81","author":"V Kumarasamy","year":"2021","journal-title":"Cancer Res"},{"key":"pone.0273182.ref044","doi-asserted-by":"crossref","DOI":"10.1016\/j.ccell.2021.08.009","article-title":"Expanding control of the tumor cell cycle with a CDK2\/4\/6 inhibitor","volume":"39","author":"K Freeman-Cook","year":"2021","journal-title":"Cancer Cell"},{"key":"pone.0273182.ref045","doi-asserted-by":"crossref","DOI":"10.1016\/j.chembiol.2019.05.005","article-title":"Multiomics Profiling Establishes the Polypharmacology of FDA-Approved CDK4\/6 Inhibitors and the Potential for Differential Clinical Activity","volume":"26","author":"M Hafner","year":"2019","journal-title":"Cell Chem Biol"},{"key":"pone.0273182.ref046","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.cell.2013.08.062","article-title":"The proliferation-quiescence decision is controlled by a bifurcation in CDK2 activity at mitotic exit","volume":"155","author":"SL Spencer","year":"2013","journal-title":"Cell"},{"key":"pone.0273182.ref047","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/S1097-2765(03)00287-9","article-title":"Multisite phosphorylation by Cdk2 and GSK3 controls cyclin E degradation","volume":"12","author":"M Welcker","year":"2003","journal-title":"Mol Cell"},{"key":"pone.0273182.ref048","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1101\/gad.10.16.1979","article-title":"Turnover of cyclin E by the ubiquitin-proteasome pathway is regulated by cdk2 binding and cyclin phosphorylation","volume":"10","author":"BE Clurman","year":"1996","journal-title":"Genes Dev"},{"key":"pone.0273182.ref049","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1093\/bioinformatics\/btp026","article-title":"KEA: kinase enrichment analysis","volume":"25","author":"A Lachmann","year":"2009","journal-title":"Bioinformatics"},{"key":"pone.0273182.ref050","article-title":"PD 0332991, a selective cyclin D kinase 4\/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro","author":"RS Finn","year":"2009","journal-title":"Breast Cancer Research"},{"key":"pone.0273182.ref051","doi-asserted-by":"crossref","first-page":"e000505","DOI":"10.1136\/esmoopen-2019-000505","article-title":"Importance of genetic screens in precision oncology","volume":"4","author":"A Mulero-S\u00e1nchez","year":"2019","journal-title":"ESMO Open"},{"key":"pone.0273182.ref052","doi-asserted-by":"crossref","DOI":"10.1016\/j.ccell.2017.11.006","article-title":"Genomic Aberrations that Activate D-type Cyclins Are Associated with Enhanced Sensitivity to the CDK4 and CDK6 Inhibitor Abemaciclib","volume":"32","author":"X Gong","year":"2017","journal-title":"Cancer Cell"},{"key":"pone.0273182.ref053","first-page":"12","article-title":"Combined CDK2 and CDK4\/6 Inhibition Overcomes Palbociclib Resistance in Breast Cancer by Enhancing Senescence","author":"K Pandey","year":"2020","journal-title":"Cancers"},{"key":"pone.0273182.ref054","article-title":"CRL4AMBRA1 is a master regulator of D-type cyclins","author":"D Simoneschi","year":"2021","journal-title":"Nature"},{"key":"pone.0273182.ref055","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2020.03.008","article-title":"Senescence-Induced Vascular Remodeling Creates Therapeutic Vulnerabilities in Pancreas Cancer","volume":"181","author":"M Ruscetti","year":"2020","journal-title":"Cell"},{"key":"pone.0273182.ref056","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1186\/s13059-014-0550-8","article-title":"Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2","volume":"15","author":"MI Love","year":"2014","journal-title":"Genome Biol"},{"key":"pone.0273182.ref057","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1038\/nbt.3536","article-title":"CRISPR knockout screening outperforms shRNA and CRISPRi in identifying essential genes","volume":"34","author":"B Evers","year":"2016","journal-title":"Nat Biotechnol"},{"key":"pone.0273182.ref058","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1101\/gad.9.11.1340","article-title":"Regulation of the retinoblastoma protein-related p107 by G1 cyclin complexes","volume":"9","author":"RL Beijersbergen","year":"1995","journal-title":"Genes Dev"},{"key":"pone.0273182.ref059","doi-asserted-by":"crossref","first-page":"15545","DOI":"10.1073\/pnas.0506580102","article-title":"Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles","volume":"102","author":"A Subramanian","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"pone.0273182.ref060","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1186\/s12859-016-1069-7","article-title":"SeqPurge: highly-sensitive adapter trimming for paired-end NGS data","volume":"17","author":"M Sturm","year":"2016","journal-title":"BMC Bioinformatics"},{"key":"pone.0273182.ref061","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1038\/s41587-019-0201-4","article-title":"Graph-based genome alignment and genotyping with HISAT2 and HISAT-genotype","volume":"37","author":"D Kim","year":"2019","journal-title":"Nat Biotechnol"},{"key":"pone.0273182.ref062","doi-asserted-by":"crossref","first-page":"E5593","DOI":"10.1073\/pnas.1419161111","article-title":"rMATS: robust and flexible detection of differential alternative splicing from replicate RNA-Seq data","volume":"111","author":"S Shen","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"pone.0273182.ref063","doi-asserted-by":"crossref","DOI":"10.1016\/j.ccell.2019.01.010","article-title":"Targeting an RNA-Binding Protein Network in Acute Myeloid Leukemia","volume":"35","author":"E Wang","year":"2019","journal-title":"Cancer Cell"},{"key":"pone.0273182.ref064","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1186\/1471-2105-14-128","article-title":"Enrichr: interactive and collaborative HTML5 gene list enrichment analysis tool","volume":"14","author":"EY Chen","year":"2013","journal-title":"BMC Bioinformatics"},{"key":"pone.0273182.ref065","doi-asserted-by":"crossref","DOI":"10.3390\/cells10030610","article-title":"Resistance of Hypoxic Cells to Ionizing Radiation Is Mediated in Part via Hypoxia-Induced Quiescence","volume":"10","author":"A Menegakis","year":"2021","journal-title":"Cells"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0273182","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,6]],"date-time":"2022-09-06T13:42:23Z","timestamp":1662471743000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0273182"}},"subtitle":[],"editor":[{"given":"Wei","family":"Xu","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2022,9,6]]},"references-count":65,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2022,9,6]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0273182","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2021.10.18.464788","asserted-by":"object"}]},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,6]]}}}